4SCAR19U T Cells Targeting B Cell Malignancies

NCT05995015 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

B Cell Malignancies

Interventions

BIOLOGICAL: Universal CD19-specific CAR gene-engineered T cells

Sponsor

Shenzhen Geno-Immune Medical Institute